Clostridium difficile Colitis
Filed under Critical Care Medicine
This article have been viewed 713 times
146 Clostridium difficile Colitis
John G. Bartlett
Antibiotic-associated colitis was recognized soon after antibiotics were introduced in the 1940s, but the cause was not known until 1978 with the original reports of the role of Clostridium difficile as the putative agent in nearly all cases of antibiotic-associated pseudomembranous colitis and 10% to 15% of those with uncomplicated antibiotic-associated diarrhea.1 Subsequent work has identified the pathophysiology, epidemiology, diagnostic methods, and treatment for this condition. The major challenges continue to be prevention and the management of patients with advanced disease, particularly those with ileus.
C. difficile causes a spectrum of enteric complications of antibiotic use ranging from nuisance diarrhea to severe and sometimes life-threatening pseudomembranous colitis. There are occasional cases of antibiotic-associated colitis due to other pathogens (Staphylococcus aureus, Klebsiella oxytoca, enterotoxin-producing strains of Clostridium perfringens or Salmonella), but most cases are either due to C. difficile or are enigmatic.2
There are six relevant issues:
1 Colonization with C. difficile: this organism is found in the colonic flora of 2% to 3% of healthy adults and 20% to 30% of hospitalized patients.3
2 Toxin production: C. difficile produces two toxins, designated toxin A and toxin B.5 Early studies implicated toxin A as the major cause of enteric toxin based on animal studies that showed florid colitis with injection of toxin A into bowel loops, but more recent studies establish that toxin B is critical for clinical expression.5 Most strains of C. difficile produce both toxins, but about 1% to 2% produce only toxin B.6
3 Antibiotic exposure: this is the most important identifiable risk and presumably reflects the impact of the inducing agent on the colonic flora, establishing the opportunity for C. difficile to convert from the spore form to the vegetative form, with replication and toxin production. Virtually every antibiotic with an antibacterial spectrum has been implicated, but the most frequent are clindamycin and broad-spectrum cephalosporins. In current practice, fluoroquinolones account for the majority of cases, presumably reflecting their enormous usage rates.4 Particularly important in recent years is the NAP-1 strain which is associated with fluoroquinolone use (see 5 below).
4 Epidemiology: C. difficile is relatively infrequent in ambulatory persons, but rates of colonization and disease are much higher as a result of exposure to the hospital environment.3 C. difficile now represents an important and potentially lethal nosocomial pathogen. Nursing homes are another setting in which there is clustering of vulnerable patients with high rates of antibiotic use where C. difficile may be endemic or epidemic.6 In the period 2001-2006, the NAP-1 strain emerged as an important epidemic agent of C. difficile in Canada, the United States, and Europe.4,6 This strain appears to be particularly virulent, with increased toxin production, mortality, treatment failure, and relapses.
5 Age: there is increasing susceptibility to the development of C. difficile colitis with age, possibly due to immunosenescence.
6 Immunologic susceptibility: many patients harbor toxigenic strains of C. difficile, with no clinical expression despite extensive antibiotic exposure. One reason for this paradox is the apparent immune protection due to the presence of neutralizing antibody to toxins A and B. This observation accounts for the increasing interest in monoclonal antibodies to toxins A and B for treatment and vaccines for prevention.7
Clinical Signs and Symptoms
The typical presentation of Clostridium difficile infection (CDI) is watery diarrhea associated with cramps.2 Other common features are fecal leukocytes, endoscopy showing PMC or colitis, characteristic changes on computed tomography (CT) (thickened bowel restricted to the colon, often associated with ascites), fever, hypoalbuminemia, and leukocytosis, sometimes with a leukemoid reaction. Nearly all cases of CDI are associated with diarrhea, but occasional postoperative patients will not have this owing to ileus. The laboratory clue that best predicts this diagnosis and its severity is the white blood cell (WBC) count. The average is about 15,000 cells/mL, but it may be much higher with counts over 20,000 or even 50,000 cells/mL. This strongly supports the CDI diagnosis and predicts severe disease.8
The diagnosis is based on detection of the C. difficile (culture, EIA for glutamine dehydrogenase or polymerase chain reaction [PCR] for toxigenic C. difficile) or its toxins, designated toxin A and toxin B (enzyme immunoassay [EIA] for toxins A + B, or cytotoxin assay). Relative merits are shown in Table 146-1.
TABLE 146-1 Diagnostic Tests for Clostridium difficile Infection
Most important to treatment of CDI is discontinuing the implicated antibiotic. If there is a need for antibiotic treatment, select a drug that is unlikely to cause CDI (narrow-spectrum β-lactams, macrolides, aminoglycosides, antistaphylococcal drugs, tetracyclines; Table 146-2). The two favored drugs for treatment of CDI are metronidazole and vancomycin, both given by mouth.1,6,7 Metronidazole is often preferred because it is less expensive. Earlier studies showed it to work as well as vancomycin, but more recent trials show oral vancomycin is superior to metronidazole in seriously ill patients,8 defined as having a WBC over 15,000 cells/mL or elevated creatinine to 1.5 × baseline.6
Buy Membership for Critical Care Medicine Category to continue reading. Learn more here
Toxic Megacolon and Ogilvie's Syndrome
Selective Decontamination of the Digestive Tract
Metronidazole and Other Antibiotics for Anaerobic Infections
Bedside Laparoscopy in the Intensive Care Unit
Peritonitis and Intraabdominal Infection
Hepatorenal Syndrome
Macrolides
Other Embolic Syndromes
SPEC - Textbook of Critical Care 12 Month Subscription